{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:48:34Z","timestamp":1791254914367,"version":"4.1.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec id=\"ab-ioi260045-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Serologic immunity to hepatitis A virus (HAV) and hepatitis B virus (HBV) protects against acute infection and severe outcomes among high-risk groups; however, contemporary data on population-level immunity remain limited, especially in high-risk populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260045-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the prevalence and factors associated with serologic immunity in the overall population and across high-risk subgroups, including those with chronic liver disease (CLD), chronic kidney disease, diabetes, and immunosuppression and pregnant people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260045-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cross-sectional study used data from the National Health and Nutrition Examination Survey from January 2017 to August 2023 and included adults aged 20 years or older with available HAV and HBV serologic test results. Data were analyzed from January 3 to May 10, 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260045-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were the prevalence of serologic immunity to HAV, defined by hepatitis A antibody positivity, and HBV, defined by hepatitis B surface antibody positivity, with vaccine-derived immunity specifically identified by surface antibody positivity in the absence of hepatitis B core antibodies. Data were weighted to generate nationally representative estimates of the US adult population. Multivariable survey-weighted logistic regression models were used to identify independent factors associated with viral hepatitis immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260045-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 13\u202f514 individuals, representing an estimated 226.1 million US adults (mean [SE] age, 48.65 [0.40] years; 51.76% female), 39.5% (95% CI, 37.7%-41.3%) demonstrated serologic immunity to hepatitis A, corresponding to approximately 89.4 million individuals. For HBV, 27.1% (95% CI, 25.8%-28.4%) demonstrated serologic immunity, corresponding to approximately 61.3 million individuals, while vaccine-derived immunity was present in 25.2% (95% CI, 23.9%-26.5%). In adjusted models, HAV immunity was associated with younger age (eg, 20-29 vs \u226565 years: adjusted odds ratio [AOR], 0.51; 95% CI, 0.44-0.60); lower educational attainment (eg, &amp;amp;lt;grade 9 vs college graduate or above: AOR, 0.32; 95% CI, 0.24-0.42); non-Hispanic Black (AOR, 1.67; 95% CI, 1.34-2.09), Mexican American (AOR, 4.22; 95% CI, 3.42-5.21), other Hispanic (AOR, 2.01; 95% CI, 1.60-2.54), non-Hispanic Asian (AOR, 3.03; 95% CI, 2.45-3.76), and multiracial or other (AOR, 1.36; 95% CI, 1.04-1.79) race and ethnicity; being born outside the US (AOR, 4.54; 95% CI, 3.74-5.52); and liver disease awareness (OR, 1.65; 95% CI, 1.29-2.09). Obesity was associated with lower odds of HAV immunity (AOR, 0.83; 95% CI, 0.72-0.96). Vaccine-derived HBV immunity was associated with younger age (eg, 20-29 vs \u226565 years: AOR, 0.18; 95% CI, 0.15-0.23), female sex (AOR, 1.36; 95% CI, 1.18-1.56), non-Hispanic Asian (AOR, 1.47; 95% CI, 1.17-1.86) and non-Hispanic Black (AOR, 1.15; 95% CI, 1.00-1.32) race and ethnicity, and higher educational attainment (eg, &amp;amp;lt;grade 9 vs college graduate or above: AOR, 3.29; 95% CI, 2.35-4.61). In high-risk subgroups, HAV immunity ranged from 26.7% (95% CI, 18.9%-34.4%) for metabolic dysfunction\u2013associated alcohol-related liver disease to 63.7% (95% CI, 50.0%-77.4%) for chronic HBV infection, while HBV vaccine-derived immunity ranged from 14.0% (95% CI, 11.3%-16.6%) for chronic kidney disease to 38.6% (95% CI, 28.0%-49.1%) for pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260045-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cross-sectional study found that population-level serologic immunity to HAV and HBV was suboptimal and substantial susceptibility persisted across high-risk clinical subgroups. These findings highlight persistent gaps in viral hepatitis protection and support targeted, systematic vaccination strategies for HAV and HBV, especially among high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.3831","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:32Z","timestamp":1786980632000},"page":"1213","source":"Crossref","is-referenced-by-count":1,"title":["Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations"],"prefix":"10.1001","volume":"186","author":[{"given":"Giovanni A.","family":"Roldan","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Davie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Leventhal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lake","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prowpanga","family":"Udompap","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis"},{"name":"Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10049","key":"ioi260045r1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"ioi260045r2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cmi.2025.11.026","article-title":"Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis.","volume":"32","author":"Sandulescu","year":"2026","journal-title":"Clin Microbiol Infect"},{"issue":"10381","key":"ioi260045r3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B.","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"ioi260045r4","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1093\/infdis\/jiae087","article-title":"The burden of hepatitis A outbreaks in the United States: health outcomes, economic costs, and management strategies.","volume":"230","author":"Horn","year":"2024","journal-title":"J Infect Dis"},{"issue":"5","key":"ioi260045r5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3201\/eid2605.191224","article-title":"Hepatitis A hospitalization costs, United States, 2017.","volume":"26","author":"Hofmeister","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"RR-13","key":"ioi260045r7","first-page":"1","article-title":"Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination\u2014recommendations of the Immunization Practices Advisory Committee (ACIP).","volume":"40","year":"1991","journal-title":"MMWR Recomm Rep"},{"key":"ioi260045r8","doi-asserted-by":"publisher","DOI":"10.1177\/00333549231175548","article-title":"Progress and unfinished business: hepatitis B in the United States, 1980-2019.","author":"Bixler","journal-title":"Public Health Rep"},{"issue":"48","key":"ioi260045r10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.15585\/mmwr.mm7348a3","article-title":"Updated recommendation for universal hepatitis B vaccination in adults aged 19-59 years: United States, 2024.","volume":"73","author":"Sandul","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"ioi260045r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","article-title":"Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020.","volume":"69","author":"Nelson","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"ioi260045r12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2021.02.008","article-title":"Low prevalence of vaccination or documented immunity to hepatitis A and hepatitis B viruses among individuals with chronic liver disease.","volume":"134","author":"Wong","year":"2021","journal-title":"Am J Med"},{"key":"ioi260045r13","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002202","article-title":"Prevalence of MASLD, Met-ALD, and ALD and associated fibrosis among US Adults: insights from NHANES 2017 to 2023.","author":"Paik","journal-title":"J Clin Gastroenterol"},{"issue":"9596","key":"ioi260045r14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"ioi260045r15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"19","key":"ioi260045r16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi260045r17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2025.10.295","article-title":"Hepatitis B vaccination: a remarkable success story that must continue.","volume":"170","author":"Lok","year":"2026","journal-title":"Gastroenterology"},{"issue":"4","key":"ioi260045r18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/hep.24510","article-title":"Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population.","volume":"54","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"issue":"42","key":"ioi260045r19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.15585\/mmwr.mm7242a1","article-title":"Mortality Investigators. Preventable deaths during widespread community hepatitis A outbreaks: United States, 2016\u20132022.","volume":"72","author":"Hofmeister","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ioi260045r20","doi-asserted-by":"publisher","DOI":"10.1177\/00333549231184007","article-title":"Trends and opportunities: hepatitis A virus infection, seroprevalence, and vaccination coverage\u2014United States, 1976-2020.","author":"Hofmeister","journal-title":"Public Health Rep"},{"issue":"2","key":"ioi260045r21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.30831","article-title":"Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016.","volume":"71","author":"Le","year":"2020","journal-title":"Hepatology"},{"issue":"39","key":"ioi260045r22","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1016\/j.vaccine.2021.08.056","article-title":"Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.","volume":"39","author":"Lewin","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"ioi260045r23","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1093\/cid\/ciaa298","article-title":"Susceptibility to hepatitis A virus infection in the United States, 2007-2016.","volume":"71","author":"Yin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ioi260045r24","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/hep.31991","article-title":"Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013-2018.","volume":"74","author":"Roberts","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"ioi260045r26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1053\/j.gastro.2006.01.007","article-title":"Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor.","volume":"130","author":"Elinav","year":"2006","journal-title":"Gastroenterology"},{"issue":"7","key":"ioi260045r27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-2036.2004.01906.x","article-title":"Review article: hepatitis vaccination in patients with chronic liver disease.","volume":"19","author":"Reiss","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"ioi260045r28","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/SMJ.0b013e3181fae4e8","article-title":"Importance of hepatitis vaccination in patients with chronic liver disease.","volume":"103","author":"Kumar","year":"2010","journal-title":"South Med J"},{"issue":"2","key":"ioi260045r29","first-page":"201","article-title":"Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?","volume":"90","author":"Keeffe","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"ioi260045r30","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1016\/j.amjmed.2005.07.013","article-title":"Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination.","volume":"118","author":"Keeffe","year":"2005","journal-title":"Am J Med"},{"issue":"2","key":"ioi260045r31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14309\/ajg.0000000000000966","article-title":"Alcohol intake and mortality in patients with chronic viral hepatitis: a nationwide cohort study.","volume":"116","author":"Sinn","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ioi260045r32","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000829","article-title":"Low awareness of MASLD among U.S. adults: trends from NHANES 2017-2023.","volume":"9","author":"Alp","year":"2025","journal-title":"Hepatol Commun"},{"issue":"1","key":"ioi260045r33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cgh.2019.05.047","article-title":"Gaps in viral hepatitis awareness in the United States in a population-based study.","volume":"18","author":"Zhou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4S1","key":"ioi260045r34","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation.","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"issue":"4","key":"ioi260045r35","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"ioi260045r36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ndt\/gfv443","article-title":"Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"32","author":"Mulley","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ioi260045r37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/pubmed\/fdaf008","article-title":"Interventions in primary care to increase uptake of adult vaccines: a systematic review.","volume":"47","author":"Wheeler","year":"2025","journal-title":"J Public Health (Oxf)"},{"issue":"9","key":"ioi260045r38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3899\/jrheum.200806","article-title":"Improving pneumococcal vaccination rates in rheumatology patients by using best practice alerts in the electronic health records.","volume":"48","author":"Sheth","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"ioi260045r39","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.amepre.2020.03.020","article-title":"Physicians\u2019 use of evidence-based strategies to increase adult vaccination uptake.","volume":"59","author":"Hurley","year":"2020","journal-title":"Am J Prev Med"},{"issue":"10","key":"ioi260045r40","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70239","article-title":"Effectiveness of a personal vaccination recommendation letter to liver transplant patients and family physicians for improving the vaccination status: improving vaccinations: whom to contact?","volume":"39","author":"Dehnen","year":"2025","journal-title":"Clin Transplant"},{"key":"ioi260045r41","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.14309\/ajg.0000000000003641.08","article-title":"Vaccination outcomes and recommendations among older adults in a gastroenterology and hepatology practice.","volume":"120","author":"Lutz","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"ioi260045r42","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.4161\/hv.34393","article-title":"The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy.","volume":"10","author":"Bagheri-Jamebozorgi","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"ioi260045r43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiw142","article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen.","volume":"214","author":"Simons","year":"2016","journal-title":"J Infect Dis"},{"issue":"13","key":"ioi260045r44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ioi260045r6","unstructured":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. World Health Organization. July 18, 2022. Accessed January 19, 2026. https:\/\/www.who.int\/publications\/i\/item\/9789240053779"},{"key":"ioi260045r9","unstructured":"ACIP recommends individual-based decision-making for hepatitis B vaccine for infants born to women who test negative for the virus. Centers for Disease Control and Prevention. December 5, 2025. Accessed January 19, 2026. https:\/\/www.cdc.gov\/media\/releases\/2025\/2025-acip-recommends-individual-based-decision-making-for-hepatitis-b-vaccine-for-infants-born-to-women.html"},{"key":"ioi260045r25","unstructured":"Pre-arrival medical screening and interventions for newly arrived refugees, immigrants, and migrants. Centers for Disease Control and Prevention. 2025. Accessed May 6, 2026. https:\/\/www.cdc.gov\/yellow-book\/hcp\/refugees-immigrants-migrants\/pre-arrival-medical-screening-and-interventions.html"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2852503\/jamainternal_roldan_2026_oi_260045_1789769195.8001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:52Z","timestamp":1791212452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2852503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.3831","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}